Louis Artime joined the Corporate Group of Skadden’s Tokyo office in March 2014 from the firm’s New York office, where he practiced in the Mergers and Acquisitions and Intellectual Property and Technology groups since 2010. Mr. Artime’s experience includes advising public and private companies in a broad range of general corporate and IP/IT-related transactions, including U.S. and cross-border mergers and acquisitions, spin-offs, and divestitures and financings.

Some of the more significant engagements in which Mr. Artime has been involved include:

  • the $3.5 billion acquisition by Otsuka Pharmaceutical Co., Ltd. of Avanir Pharmaceuticals, Inc. and its $886 million acquisition of Astex Pharmaceuticals, Inc.;
  • an agreement by Miraca Holdings, Inc. to form a genetic testing service joint venture company with Baylor College of Medicine;
  • the $1.1 billion acquisition by Sumitomo Mitsui Banking Corporation of Flagship Rail Services LLC;
  • the $2.6 billion initial public offering by Pfizer Inc. of its animal health business and the related research, development and collaboration agreement and intellectual property license agreements between Pfizer Inc. and Zoetis Inc.;
  • the acquisition by Furukawa Electric Co. Ltd. of SuperPower Inc. from the Philips Group;
  • the $621 million acquisition by Jackson National Life Insurance Company of the U.S. life reinsurance operations of Swiss Re; and
  • the $267.5 million acquisition by J.C. Penney from Liz Claiborne Inc. of the worldwide rights to the LIZ CLAIBORNE family of brands as well as the United States and Puerto Rico rights for the MONET jewelry brand.

Mr. Artime took leave from Skadden from September 2012 to June 2013 in order to complete advanced Japanese language study at the Inter-University Center for Japanese Language Studies in Yokohama, Japan, administered by Stanford University.



  • J.D., University of Michigan Law School, 2009
  • B.A., Washington University in St. Louis, 2005


  • New York


  • Japanese

Louis Artime